Atricure Inc. Stock
Atricure Inc. Stock
Atricure Inc. dominated the market today, gaining €1.00 (3.250%).
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Atricure Inc..
As a result the target price of 46 € shows a positive potential of 44.65% compared to the current price of 31.8 € for Atricure Inc..
Pros and Cons of Atricure Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | 3.250% | -3.750% | -7.229% | -50.323% | -9.412% | -50.323% | -38.400% |
| SI-BONE Inc | 1.460% | -2.837% | -17.964% | -16.970% | -18.935% | - | - |
| Orasure Tech | 0.000% | 9.821% | 21.782% | -35.602% | 19.417% | -51.287% | -79.500% |
| Lantheus Holdings Inc | -1.450% | -1.028% | -2.717% | -35.764% | -2.343% | -0.250% | - |
Comments
AtriCure (NASDAQ:ATRC) had its price target raised by analysts at JPMorgan Chase & Co. from $42.00 to $48.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure, Inc. (NASDAQ: ATRC) had its price target raised by analysts at Needham & Company LLC from $44.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure, Inc. (NASDAQ: ATRC) had its price target lowered by analysts at UBS Group AG from $60.00 to $58.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on
